Compare BHVN & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHVN | ATRC |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2022 | 2005 |
| Metric | BHVN | ATRC |
|---|---|---|
| Price | $14.34 | $48.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $29.08 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 1.9M | 780.7K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.08 | ★ 74.74 |
| EPS | N/A | ★ 0.18 |
| Revenue | N/A | ★ $201,630,000.00 |
| Revenue This Year | N/A | $15.27 |
| Revenue Next Year | N/A | $12.21 |
| P/E Ratio | ★ N/A | $273.78 |
| Revenue Growth | N/A | ★ 15.40 |
| 52 Week Low | $7.48 | $25.36 |
| 52 Week High | $18.57 | $49.88 |
| Indicator | BHVN | ATRC |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 79.77 |
| Support Level | $13.84 | $26.47 |
| Resistance Level | $15.04 | N/A |
| Average True Range (ATR) | 0.66 | 1.61 |
| MACD | -0.06 | 0.37 |
| Stochastic Oscillator | 42.13 | 89.12 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.